Treatment

0.9% sodium chloride, GADOTERIC ACID clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic exploratory (Phase II)
An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants with Relapsing Multiple Sclerosis
This study is looking into a new medicine, LY3541860, for people with relapsing multiple sclerosis (RMS). Researchers want to see if it can reduce the number of new spots on the brain (lesions) compared to a dummy treatment (placebo).
For: Relapsing Multiple Sclerosis
Italy · Lithuania · Germany